Cabaletta Bio Q2 2026: $51M Net Loss, Going Concern Warning Despite $225M Cash
CABA has more than doubled off its 52-week low of $1.26.
Summary
Cabaletta Bio's Q2 2026 10-Q shows a widening net loss and a going concern warning, despite a cash position that funds operations into mid-2027. The filing also details outstanding warrants and recent financing activities.
Key Events · Earnings and Guidance · CABA
-
Q2 Net Loss Widens
Net loss of $51.0 million for Q2 2026, compared to $45.1 million in Q2 2025, driven by higher R&D spending on rese-cel clinical trials and manufacturing.
-
Going Concern Warning Reiterated
Management states substantial doubt exists about the company's ability to continue as a going concern, despite $225.1 million in cash and cash equivalents as of June 30, 2026.
-
Cash Runway into Mid-2027
The company expects current cash to fund operations into mid-2027, but will need additional capital to complete clinical development and commercialization.
-
Warrant Overhang
47,815,090 common stock warrants with a $2.50 exercise price expire on September 12, 2026; if exercised for cash, they would provide approximately $120 million in gross proceeds but cause significant dilution.
Analysis · CABA · Life Sciences
Cabaletta Bio reported a $51.0 million net loss for Q2 2026, up from $45.1 million a year earlier, while holding $225.1 million in cash. The company reiterated that substantial doubt exists about its ability to continue as a going concern, even though its cash runway extends into mid-2027. The filing also reveals 47.8 million outstanding warrants expiring September 12, 2026, which could add significant dilution if exercised.
At the time of this filing, CABA was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $1.26 to $4.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.